Logo
CustomersBlogPricingDemo
SIGN UP NOWBOOK A DEMO

What is the Fiscal Year for Revolution Medicines?

Date: November 13, 2026


Revolution Medicines's current fiscal year starts on January 1, 2026, and ends on December 31, 2026. Their current quarter is Q4, which ends on December 31, 2026.

Current Fiscal Year Overview

Fiscal Year Start
January 1, 2026
Fiscal Year End
December 31, 2026
Current Quarter
Q4
Current Quarter End
December 31, 2026

Quarterly Breakdown

Q1

Jan 1, 2026 – Mar 31, 2026

Q2

Apr 1, 2026 – Jun 30, 2026

Q3

Jul 1, 2026 – Sep 30, 2026

Q4

Oct 1, 2026 – Dec 31, 2026

Company Information

Headquarters

Redwood City, California

Industry

Biotechnology Research

Stock Symbol

RVMD

Website
https://revmed.com
Description

At Revolution Medicines, we aim to change the trajectory of disease for patients living with RAS-addicted cancers around the world. We challenge assumptions, act on what the science reveals, and push beyond convention to tackle some of the most difficult-to-treat cancers. Our differentiated, platform-driven approach targets RAS in its active, ON state—unlocking a fundamentally new way to inhibit RAS. We are advancing a broad, integrated pipeline of inhibitors with the ambition to establish RAS(ON) inhibition as the backbone for treating RAS-addicted cancers while continuing to pioneer the next generation of innovation. We follow the science and act on it with urgency to turn insights into new treatments—because for patients, the stakes are deeply personal, measured in time and quality of life. For additional information on our guidelines, please visit https://www.revmed.com/social-media-community-guidelines/


Use Salesmotion for Account Data and Insights

Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Revolution Medicines and uncover key business information that drives smarter conversations.

Book a demo today to strengthen your sales strategy with powerful data and actionable insights.

BOOK A DEMO